Surrozen, Inc.
NASDAQ:SRZNBiotechnology
-$1.14 today
- Market cap
- $237.33M
- Beta
- 0.51
- P/E (TTM)
- -0.7
- EPS (TTM)
- -$31.29
Volume 0.31M
Average 0.11M
SRZN Total Current Assets
All assets expected to be converted to cash or used up within one year.
Surrozen, Inc.NASDAQ: SRZN
Total Current Assets · Q1 FY2026 · quarter ended Mar 2026
Total current assets rises 7.5% from a year ago
Total current assets stood at $113.95M at the end of Q1 FY2026, up 7.5% from a year earlier and up 24.5% from the prior quarter. Over 3 fiscal years it compounded at +4.0% a year.
Context
- Total current assets amounted to 94.4% of total assets at the end of Q1 FY2026, up 2.1 pp from a year earlier.
- Total current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +7.5% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 91.56M USD
- Year-over-year change
- +135.2%
- 4-year CAGR
- -3.4%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 91.56M | +135.2% |
| FY2024 | 2024-12-31 | 38.93M | -5.3% |
| FY2023 | 2023-12-31 | 41.13M | -49.4% |
| FY2022 | 2022-12-31 | 81.31M | -22.7% |
| FY2021 | 2021-12-31 | 105.19M | — |
Total Current Assets vs competitors
How SRZN compares with its peers on the latest reported figures
- SRZN's Mar 2026 total current assets of $113.95M is the 3rd highest of the 8 companies compared; the peer median is $92.27M.
- Its year-over-year change of +7.5% is the 6th highest of 8, against a peer median of +56.6%.
- Total current assets amounts to 94.4% of total assets for SRZN, versus a peer median of 96.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $188.3M | -14.1% | -10.8% | 93.9% | |
| Mar 2026 | $181.59M | -28.9% | -22.6% | 66.7% | |
| Mar 2026 | $113.95M | +7.5% | +4.0% | 94.4% | |
| Mar 2026 | $95.28M | +311.8% | -14.5% | 51.1% | |
| Mar 2026 | $92.27M | +449.9% | +89.4% | 96.3% | |
IRDOpus Genetics, Inc. | Mar 2026 | $66.6M | +39.0% | +0.7% | 99.7% |
| Mar 2026 | $35.81M | +56.6% | +0.2% | 99.1% | |
| Mar 2026 | $10.51M | +282.0% | — | 100.0% | |
| Peer median (excluding SRZN) | $92.27M | +56.6% | -5.3% | 96.3% | |
Competitors are the stored peer set for SRZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 33.09M | 24.69M | 36.04M | 34.57M | 89.25M |
| Short-term Investments | 68.76M | 51.15M | 0 | 0 | 0 |
| Net Receivables | 0 | 1.98M | 2.15M | 2.54M | 208K |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 0 | 756K | 580K | 671K | 2.11M |
| Total Current Assets | 105.19M | 81.31M | 41.13M | 38.93M | 91.56M |
| Property, Plant & Equipment (Net) | 9.38M | 6.9M | 3.86M | 8.36M | 6.43M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 21.66M | 0 | 688K | 0 | 688K |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 954K | 1.23M | 402K | 1.17M | 46K |
| Total Non-current Assets | 31.99M | 8.13M | 4.95M | 9.54M | 7.17M |
| Total Assets | 137.17M | 89.44M | 46.08M | 48.47M | 98.73M |
| Account Payables | 2.72M | 658K | 525K | 306K | 728K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 589K | 581K | 292K | 191K | 289K |
| Total Current Liabilities | 13.57M | 9.73M | 7.15M | 7.32M | 9.93M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 8.3M | 326K | 115K | 55.89M | 271.21M |
| Total Non-current Liabilities | 13.9M | 3.7M | 997K | 62.53M | 276.56M |
| Total Liabilities | 27.47M | 13.43M | 8.15M | 69.85M | 286.49M |
| Common Stock | 4K | 0 | 0 | 0 | 1K |
| Retained Earnings | (142.65M) | (178.65M) | (221.7M) | (285.26M) | (527.29M) |
| Accumulated OCI | (119K) | (241K) | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 109.7M | 76M | 37.94M | (21.38M) | (187.76M) |
| Total Debt | 7.79M | 5.6M | 3.38M | 8.47M | 6.64M |
| Net Debt | (25.3M) | (19.09M) | (32.66M) | (26.1M) | (82.61M) |
Surrozen, Inc.
NASDAQ:SRZN
Intrinsic Alpha fair value
Locked
Current Price
$31.74
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.